Català Raquel, Cabré Anna, Hernández-Flix Salvador, Ferré Raimón, Sangenís Sandra, Plana Núria, Texidó Anna, Masana Lluís
Sleep Disorders Unit, Respiratory Department, Reus, Spain ; "Sant Joan" University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Spain.
Sleep. 2013 Dec 1;36(12):1831-7. doi: 10.5665/sleep.3210.
To evaluate circulating adipocyte and epidermal fatty acid-binding protein (FABP4 and FABP5) concentrations in patients with obstructive sleep apnea (OSA), as well as the effects of continuous positive airway pressure (CPAP) treatment.
Our cross-sectional study included 125 patients. After polysomnography, 58 participants met the criteria for CPAP treatment and were included in a closed cohort study of 8 weeks of CPAP treatment. General anthropometric and biochemical data and circulating FABP4 and FABP5 levels were determined in all patients at baseline and after CPAP treatment in those receiving this therapy.
Circulating FABP4 but not FABP5 levels were higher in patients with OSA (P = 0.003). FABP4 but not FABP5 values were associated with parameters of OSA severity independently of age, gender, adiposity and insulin resistance (P < 0.05). FABP4 but not FABP5 concentrations were determinants of OSA presence (OR: 1.11, P = 0.010) and severity (OR: 1.06, P = 0.020). After CPAP treatment, FABP4 levels decreased in the more severe patients (P = 0.019), while FABP5 levels increased in all patients (P < 0.001).
FABP4 is directly associated with obstructive sleep apnea severity and did not change with continuous positive airway pressure treatment, while FABP5 was not associated with obstructive sleep apnea severity and increased with continuous positive airway pressure treatment. FABP4 and FABP5 have different associations with obstructive sleep apnea. FABP4 but not FABP5 could be considered a marker of metabolic alterations in obstructive sleep apnea patients.
评估阻塞性睡眠呼吸暂停（OSA）患者循环中的脂肪细胞和表皮脂肪酸结合蛋白（FABP4和FABP5）浓度，以及持续气道正压通气（CPAP）治疗的效果。
我们的横断面研究纳入了125例患者。经多导睡眠监测后，58名参与者符合CPAP治疗标准，并被纳入一项为期8周的CPAP治疗封闭队列研究。在所有患者基线时以及接受该治疗的患者CPAP治疗后，测定一般人体测量学和生化数据以及循环FABP4和FABP5水平。
OSA患者循环中的FABP4水平较高，而FABP5水平无差异（P = 0.003）。FABP4值而非FABP5值与OSA严重程度参数独立相关，不受年龄、性别、肥胖和胰岛素抵抗影响（P < 0.05）。FABP4浓度而非FABP5浓度是OSA存在（OR：1.11，P = 0.010）和严重程度（OR：1.06，P = 0.020）的决定因素。CPAP治疗后，病情较重患者的FABP4水平下降（P = 0.019），而所有患者的FABP5水平升高（P < 0.001）。
FABP4与阻塞性睡眠呼吸暂停严重程度直接相关，且不随持续气道正压通气治疗而改变，而FABP5与阻塞性睡眠呼吸暂停严重程度无关，且随持续气道正压通气治疗而升高。FABP4和FABP5与阻塞性睡眠呼吸暂停有不同的关联。FABP4而非FABP5可被视为阻塞性睡眠呼吸暂停患者代谢改变的标志物。
